Integra Lifesciences Holdings Corp  

(Public, NASDAQ:IART)   Watch this stock  
Find more results for IART
+1.30 (1.57%)
Jul 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 82.58 - 84.80
52 week 54.75 - 84.80
Open 83.16
Vol / Avg. 408,705.00/384,707.00
Mkt cap 3.30B
P/E 654.83
Div/yield     -
EPS 0.13
Shares 37.36M
Beta 0.63
Inst. own 92%
Jul 28, 2016
Q2 2016 Integra LifeSciences Holdings Corp Earnings Release
Jul 28, 2016
Q2 2016 Integra LifeSciences Holdings Corp Earnings Call - Webcast
Jun 8, 2016
Integra LifeSciences Holdings Corp at Jefferies Healthcare Conference
May 25, 2016
Integra LifeSciences Holdings Corp at UBS Global Healthcare Conference
May 24, 2016
Integra LifeSciences Holdings Corp Annual Shareholders Meeting
May 20, 2016
Integra LifeSciences Holdings Corp Annual Shareholders Meeting (Estimated)
May 10, 2016
Integra LifeSciences Holdings Corp at Bank of America Merrill Lynch Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin 5.12% 0.78%
Operating margin 8.98% 9.18%
EBITD margin - 21.08%
Return on average assets 2.81% 0.41%
Return on average equity 6.51% 0.94%
Employees 3,500 -
CDP Score - -


311 Enterprise Dr
PLAINSBORO, NJ 08536-3344
United States - Map
+1-609-2750500 (Phone)
+1-609-2755363 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing and marketing of surgical implants and medical instruments. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery. Its segments include Specialty Surgical Solutions, which offers products, including specialty surgical instrumentation for a range of specialties. Its product category includes products and solutions for dural repair, precision tools and instruments, tissue ablation and neuro critical care, including product portfolios used in neurosurgery operation suites and critical care units, and Orthopedics and Tissue Technologies, which offers products of a combination of differentiated regenerative technology products for soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement hardware products for both upper extremities and lower extremities.

Officers and directors

Stuart M. Essig Chairman of the Board
Age: 54
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Peter J. Arduini President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Glenn G Coleman Chief Financial Officer, Corporate Vice President
Age: 47
Bio & Compensation  - Reuters
Padma Thiruvengadam Chief Human Resources Officer, Corporate Vice President - Strategic Initiatives and Operational Excellence
Age: 50
Bio & Compensation  - Reuters
Kenneth Burhop Ph.D. Chief Scientific Officer, Corporate Vice President
Age: 61
Bio & Compensation  - Reuters
John Mooradian Corporate Vice President - Global Operations and Supply Chain
Age: 59
Bio & Compensation  - Reuters
Richard D. Gorelick Corporate Vice President, General Counsel, Administration, Secretary
Age: 54
Bio & Compensation  - Reuters
Mark A. Augusti Corporate Vice President, President - Orthopedics and Tissue Technologies
Age: 49
Bio & Compensation  - Reuters
Robert T. Davis Jr. Corporate Vice President, President - Specialty Surgical Solutions
Age: 56
Bio & Compensation  - Reuters
Deborah Leonetti Corporate Vice President - Global Services and Repair
Age: 59
Bio & Compensation  - Reuters